Astria Therapeutics (ATXS) Stock Price, News & Analysis

Company Overview

Astria Therapeutics, Inc. is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders. Its lead clinical programs are designed to harness bispecific constructs and cell‐based activation technologies to improve the precision and durability of immune killing, while additional preclinical assets focus on expanding the scope of treatable targets and refining safety profiles.

Founded in 2018 and headquartered in San Diego, California, Astria Therapeutics collaborates with academic institutions, contract research organizations and regulatory authorities throughout North America and Europe to advance its product candidates. The company is guided by an executive team with extensive biopharmaceutical industry experience and a board of directors that brings together scientific, clinical and commercial expertise to support its strategic development plan.

Key Stats

• Today's Range: $11.70 to $12.17
• 50-Day Range: $6.18 to $8.47
• 52-Week Range: $3.56 to $12.52
• Volume: 18.15 million shs
• Average Volume: 457,538 shs
• Market Capitalization: $667.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.50
• Consensus Rating: Moderate Buy

Astria Therapeutics Stock Analysis - MarketRank™

Astria Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 622nd out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Astria Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Astria Therapeutics has a consensus price target of $29.50, representing about 248.3% upside from its current price of $8.47.

Amount of Analyst Coverage

Astria Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Astria Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Astria Therapeutics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Astria Therapeutics is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Astria Therapeutics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.49% of the float of Astria Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Astria Therapeutics has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Astria Therapeutics has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Astria Therapeutics does not currently pay a dividend.

Dividend Growth

Astria Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.49% of the float of Astria Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Astria Therapeutics has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Astria Therapeutics has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.50

News Sentiment

Astria Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Astria Therapeutics this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for ATXS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Astria Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Astria Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.50% of the stock of Astria Therapeutics is held by insiders.

Percentage Held by Institutions

98.98% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ATXS Stock Analysis - Frequently Asked Questions

How have ATXS shares performed this year?

Astria Therapeutics' stock was trading at $8.94 at the beginning of 2025. Since then, ATXS stock has decreased by 5.3% and is now trading at $8.47.

How were Astria Therapeutics' earnings last quarter?

Astria Therapeutics, Inc. (NASDAQ:ATXS) released its earnings results on Tuesday, August, 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.04.

When did Astria Therapeutics' stock split?

Astria Therapeutics shares reverse split before market open on Friday, August 20th 2021.The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Who are Astria Therapeutics' major shareholders?

Astria Therapeutics' top institutional shareholders include Voya Investment Management LLC (0.04%). Insiders that own company stock include Perceptive Advisors Llc and Christopher Morabito.
View institutional ownership trends.

How do I buy shares of Astria Therapeutics?

Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Astria Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Astria Therapeutics investors own include CRISPR Therapeutics (CRSP), Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AUO (AUOTY).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/13/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATXS
• CIK: 1454789
• Web: www.catabasis.com
• Phone: (617) 349-1971
• Fax: 617-273-2637
• Employees: 30
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Astria Therapeutics: $29.50
• High Price Target: $49.00
• Low Price Target: $20.00
• Potential Upside/Downside: +248.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$94.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.39%
• Return on Assets: -36.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.89
• Quick Ratio: 14.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.97 per share
• Price / Book: 2.13

Miscellaneous

• Outstanding Shares: 56,440,000
• Free Float: 53,895,000
• Market Cap: $478.05 million
• Optionable: Optionable
• Beta: 0.43